Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis

BACKGROUND: Miriplatin (formerly SM-11355), a novel lipophilic platinum complex developed to treat hepatocellular carcinoma, is administered into the hepatic artery using an oily lymphographic agent (Lipiodol Ultra-Fluide(®)) as a carrier. We clarified the usefulness of miriplatin as an agent for tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanada, Mitsuharu, Baba, Akemi, Tsutsumishita, Yasuyuki, Noguchi, Toshihiro, Yamaoka, Takashi, Chiba, Nobuyoshi, Nishikaku, Fumio
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691803/
https://www.ncbi.nlm.nih.gov/pubmed/19104812
http://dx.doi.org/10.1007/s00280-008-0895-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691803/
https://www.ncbi.nlm.nih.gov/pubmed/19104812
http://dx.doi.org/10.1007/s00280-008-0895-3

Ejemplares similares